Last reviewed · How we verify
MMRVNS
MMRV vaccine is a live attenuated vaccine that stimulates the body's immune response to protect against measles, mumps, rubella, and varicella.
MMRV vaccine is a live attenuated vaccine that stimulates the body's immune response to protect against measles, mumps, rubella, and varicella. Used for Protection against measles, mumps, rubella, and varicella.
At a glance
| Generic name | MMRVNS |
|---|---|
| Also known as | Investigational measles, mumps, rubella and varicella vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
MMRV vaccine contains weakened forms of the viruses that cause measles, mumps, rubella, and varicella. When administered, the vaccine triggers an immune response, producing antibodies and immune cells that can recognize and fight these viruses. This immune response helps to protect against future infections.
Approved indications
- Protection against measles, mumps, rubella, and varicella
Common side effects
- Fever
- Redness, swelling, or pain at injection site
- Fatigue
- Headache
- Muscle pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMRVNS CI brief — competitive landscape report
- MMRVNS updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI